The VP Finance & CFO of FibroGen is Exercising Options

By Carrie Williams

On November 13, the VP Finance & CFO of FibroGen, Pat Controneo, exercised options of FibroGen for $93.98K.

Following Pat Controneo’s last FGEN Buy transaction on November 07, 2016, the stock climbed by 28.7%. This recent transaction increases Pat Controneo’s holding in the company by 20.59% to a total of $8.51 million.

The company has a one-year high of $60.15 and a one-year low of $19.25. Currently, FibroGen has an average volume of 981.3K.

Eight different firms, including Citigroup and Goldman Sachs, currently also have a Buy rating on the stock.

The insider sentiment on FibroGen has been negative according to 84 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

FibroGen, Inc. operates as a science-based biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat unmet medical needs. It focuses on fibrosis and hypoxia-induced factor biology to generate programs targeting therapeutic areas. The company was founded by Thomas B.